Cure My Disease

Don't miss your cure!

 Log in / Sign up

Starving brain tumors of blood before surgery

NCT ID NCT07823985

Symptom relief Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Some brain tumors, including meningiomas, hemangioblastomas, and certain metastases, have a rich blood supply that makes surgical removal difficult and risky. This study tests whether blocking the tumor's feeding blood vessels with a catheter procedure before surgery reduces bleeding and helps surgeons remove the tumor more safely. Participants undergo imaging, the embolization procedure, and then microsurgical tumor removal within one to three days. Researchers track how much of the tumor's blood supply is cut off, how much blood is lost during surgery, and any complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Preoperative endovascular embolization, a catheter procedure that blocks the tumor's feeding blood vessels using particles, Onyx, or microcoils
What this could lead to
If it works, doctors could use this catheter technique to make surgery safer and more complete for people with highly vascular brain tumors.
What could go wrong
This is a small, single-center study with no comparison group, so results may not apply broadly. Embolization carries risks of stroke, bleeding, or vessel damage, and not every tumor can be safely reached.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of a hypervascular brain tumor (e.g., meningioma, hemangioblastoma, or hypervascular metastasis) confirmed by contrast-enhanced MRI or CT * Scheduled for preoperative endovascular embolization followed by microsurgical resection Exclusion Criteria: * Severe, uncorrected coagulopathy * Severe allergy to iodinated contrast media * Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m²) * Absence of safe arterial access * Absence of identifiable tumor-feeding vessels suitable for selective microcatheterization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm hemangioblastoma meningioma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Brain neoplasms Hemangioblastoma Meningioma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.